just wow:
"nderlying profit before tax is expected to increase by 355% to approximately £1.28 million excluding one-off costs (2016: £0.281 million on a constant currency basis) driven by a more efficient supply chain which has led to an improvement in gross margin of approximately 62% (2016: 57.4%), up 400 bps."
lovely results:
"· Full year total income expected to more than double to approaching £4 million (2016: £1.67 million).
· Growing revenue driven by continued success in winning new development partner agreements and signing follow-on agreements; on track to sign fifth development partner during 2017.
· Strong financial position - cash & short-term investments at 30 June 2017 expected to be at least £16 million"
"Overall, for the coming year, the Group anticipates a substantial increase in revenue as new capacity comes online and anticipates a less significant increase in combined R&D and administrative expenses."
... did I read that right?
"Bioverativ's agreement to acquire True North Therapeutics and its ABZENA Inside product TNT009, for consideration of up to $825 million"